235 related articles for article (PubMed ID: 26765576)
1. Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males.
Merovci A; Abdul-Ghani M; Mari A; Solis-Herrera C; Xiong J; Daniele G; Tripathy D; DeFronzo RA
J Clin Endocrinol Metab; 2016 Mar; 101(3):1249-56. PubMed ID: 26765576
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin lowers plasma glucose concentration and improves β-cell function.
Merovci A; Mari A; Solis-Herrera C; Xiong J; Daniele G; Chavez-Velazquez A; Tripathy D; Urban McCarthy S; Abdul-Ghani M; DeFronzo RA
J Clin Endocrinol Metab; 2015 May; 100(5):1927-32. PubMed ID: 25710563
[TBL] [Abstract][Full Text] [Related]
3. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes.
Bajaj M; Suraamornkul S; Kashyap S; Cusi K; Mandarino L; DeFronzo RA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4649-55. PubMed ID: 15356076
[TBL] [Abstract][Full Text] [Related]
4. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes.
Cusi K; Kashyap S; Gastaldelli A; Bajaj M; Cersosimo E
Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1775-81. PubMed ID: 17299078
[TBL] [Abstract][Full Text] [Related]
5. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin.
Mudaliar S; Henry RR; Boden G; Smith S; Chalamandaris AG; Duchesne D; Iqbal N; List J
Diabetes Technol Ther; 2014 Mar; 16(3):137-44. PubMed ID: 24237386
[TBL] [Abstract][Full Text] [Related]
6. Chronic reduction of plasma free fatty acid improves mitochondrial function and whole-body insulin sensitivity in obese and type 2 diabetic individuals.
Daniele G; Eldor R; Merovci A; Clarke GD; Xiong J; Tripathy D; Taranova A; Abdul-Ghani M; DeFronzo RA
Diabetes; 2014 Aug; 63(8):2812-20. PubMed ID: 24353180
[TBL] [Abstract][Full Text] [Related]
7. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
Bajaj M; Suraamornkul S; Romanelli A; Cline GW; Mandarino LJ; Shulman GI; DeFronzo RA
Diabetes; 2005 Nov; 54(11):3148-53. PubMed ID: 16249438
[TBL] [Abstract][Full Text] [Related]
8. Sodium-glucose cotransporter-2 inhibition improves incretin sensitivity of pancreatic β-cells in people with type 2 diabetes.
Ahn CH; Oh TJ; Kwak SH; Cho YM
Diabetes Obes Metab; 2018 Feb; 20(2):370-377. PubMed ID: 28786557
[TBL] [Abstract][Full Text] [Related]
9. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes.
Paolisso G; Tagliamonte MR; Rizzo MR; Gualdiero P; Saccomanno F; Gambardella A; Giugliano D; D'Onofrio F; Howard BV
Diabetologia; 1998 Oct; 41(10):1127-32. PubMed ID: 9794097
[TBL] [Abstract][Full Text] [Related]
10. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.
Santomauro AT; Boden G; Silva ME; Rocha DM; Santos RF; Ursich MJ; Strassmann PG; Wajchenberg BL
Diabetes; 1999 Sep; 48(9):1836-41. PubMed ID: 10480616
[TBL] [Abstract][Full Text] [Related]
11. Effect of a sustained reduction in plasma free fatty acid concentration on insulin signalling and inflammation in skeletal muscle from human subjects.
Liang H; Tantiwong P; Sriwijitkamol A; Shanmugasundaram K; Mohan S; Espinoza S; Defronzo RA; Dubé JJ; Musi N
J Physiol; 2013 Jun; 591(11):2897-909. PubMed ID: 23529132
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
Merovci A; Solis-Herrera C; Daniele G; Eldor R; Fiorentino TV; Tripathy D; Xiong J; Perez Z; Norton L; Abdul-Ghani MA; DeFronzo RA
J Clin Invest; 2014 Feb; 124(2):509-14. PubMed ID: 24463448
[TBL] [Abstract][Full Text] [Related]
13. Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients.
Vestergaard ET; Hjelholt AJ; Kuhre RE; Møller N; Larraufie P; Gribble FM; Reimann F; Jessen N; Holst JJ; Jørgensen JOL
J Clin Endocrinol Metab; 2019 Jul; 104(7):2581-2592. PubMed ID: 30726969
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes.
Daniele G; Xiong J; Solis-Herrera C; Merovci A; Eldor R; Tripathy D; DeFronzo RA; Norton L; Abdul-Ghani M
Diabetes Care; 2016 Nov; 39(11):2036-2041. PubMed ID: 27561923
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study.
Abdul-Ghani M; Migahid O; Megahed A; Singh R; Fawaz M; DeFronzo RA; Jayyousi A
Diabetes Obes Metab; 2019 Mar; 21(3):705-709. PubMed ID: 30259621
[TBL] [Abstract][Full Text] [Related]
16. Effects of prolonged fasting and sustained lipolysis on insulin secretion and insulin sensitivity in normal subjects.
Salgin B; Marcovecchio ML; Humphreys SM; Hill N; Chassin LJ; Lunn DJ; Hovorka R; Dunger DB
Am J Physiol Endocrinol Metab; 2009 Mar; 296(3):E454-61. PubMed ID: 19106250
[TBL] [Abstract][Full Text] [Related]
17. Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic Study.
Forst T; Alghdban MK; Fischer A; Weber MM; Voswinkel S; Heise T; Kapitza C; Plum-Mörschel L
Horm Metab Res; 2018 May; 50(5):403-407. PubMed ID: 29727906
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults.
Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
Eur J Endocrinol; 2003 Dec; 149(6):511-9. PubMed ID: 14640991
[TBL] [Abstract][Full Text] [Related]
19. COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
Ekholm E; Hansen L; Johnsson E; Iqbal N; Carlsson B; Chen H; Hirshberg B
Endocr Pract; 2017 Mar; 23(3):258-265. PubMed ID: 27849380
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
Davoren PM; Kelly W; Gries FA; Hubinger A; Whately-Smith C; Alberti KG
Metabolism; 1998 Mar; 47(3):250-6. PubMed ID: 9500558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
